TNFRSF4
ENSG00000186827
Target class
Membrane receptor
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
5
- Approved drugs
- 0
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- TNFRSF4
- Gene name
- TNF receptor superfamily member 4
- Gene symbol
- TNFRSF4
- Previous gene symbols
- TXGP1L
- Protein name
- Tumor necrosis factor receptor superfamily member 4 (ACT35 antigen) (OX40L receptor) (TAX transcriptionally-activated glycoprotein 1 receptor) (CD antigen CD134)
- ACT35
- OX40
- CD134
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor receptor superfamily
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 41
- Highest tissue expression
- 23.23
- Tissue specificity (Gini)
- 0.531
- Tissue specificity (tau)
- 0.861
- KEGG gene identifiers
- hsa:7293
- Reactome pathways
- R-HSA-5669034
- Protein interaction confidence
- 0.853538
- Protein interaction partners
- 39
- End position
- 1214153
- Start position
- 1211326
- Chromosome
- 1
- Strand
- Reverse
- Membrane
- Single-pass type I membrane protein.
- Tissue specificity (tau)
- 0.860931
- Expression inequality (Gini)
- 0.531283
Expression in transcripts per million
- Spleen
- 23.23
- Adipose - Visceral (Omentum)
- 15.26
- Lung
- 13.85
- Cells - EBV-transformed lymphocytes
- 11
- Thyroid
- 9.95
Expression in transcripts per million
- Spleen23.23
- Adipose - Visceral (Omentum)15.26
- Lung13.85
- Cells - EBV-transformed lymphocytes11
- Thyroid9.95
- Breast - Mammary Tissue9.48
- Adipose - Subcutaneous9.24
- Small Intestine - Terminal Ileum7.26
- Prostate6.22
- Whole Blood5.46
- Colon - Transverse4.55
- Kidney - Medulla4.3
- Cervix - Endocervix4.08
- Bladder3.83
- Cervix - Ectocervix3.41
- Fallopian Tube3.2
- Heart - Left Ventricle3.18
- Pituitary3.08
- Uterus3.07
- Artery - Coronary2.92
- Stomach2.75
- Minor Salivary Gland2.68
- Artery - Aorta2.57
- Heart - Atrial Appendage2.54
- Nerve - Tibial2.41
And 29 more, listed on the interactive page.
Biological processes
- GO:0006955
Cellular components
- GO:0005886
- GO:0005031
- GO:0005515
Related records
Trials (35)
- A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis
- A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis
- A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
- A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
- A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
- A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
- A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
- A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
- A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants
- A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
- Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
Drugs (5)
- GSK-3174998 Tumor necrosis factor receptor superfamily member 4 agonist
- Ivuxolimab Tumor necrosis factor receptor superfamily member 4 agonist
- MEDI-6469 Tumor necrosis factor receptor superfamily member 4 agonist
- Rocatinlimab Tumor necrosis factor receptor superfamily member 4 antagonist
- Telazorlimab Tumor necrosis factor receptor superfamily member 4 antagonist